Adial Pharmaceuticals Stock Current Asset
| ADIL Stock | USD 0.40 0.03 8.11% |
Fundamental analysis of Adial Pharmaceuticals allows traders to better anticipate movements in Adial Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Other Current Assets is expected to rise to about 486.8 K this year, although the value of Non Current Assets Total will most likely fall to about 537.5 K. Adial | Current Asset | Build AI portfolio with Adial Stock |
Adial Pharmaceuticals Company Current Asset Analysis
Adial Pharmaceuticals' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Adial Pharmaceuticals Current Asset | 1.02 M |
Most of Adial Pharmaceuticals' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adial Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Adial Current Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Adial Pharmaceuticals is extremely important. It helps to project a fair market value of Adial Stock properly, considering its historical fundamentals such as Current Asset. Since Adial Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Adial Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Adial Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Adial Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Adial Pharmaceuticals has a Current Asset of 1.02 M. This is 99.95% lower than that of the Pharmaceuticals sector and 99.9% lower than that of the Health Care industry. The current asset for all United States stocks is 99.99% higher than that of the company.
Adial Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adial Pharmaceuticals' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adial Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Adial Pharmaceuticals by comparing valuation metrics of similar companies.Adial Pharmaceuticals is currently under evaluation in current asset category among its peers.
Adial Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adial Pharmaceuticals from analyzing Adial Pharmaceuticals' financial statements. These drivers represent accounts that assess Adial Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adial Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 21.2M | 50.2M | 5.8M | 2.6M | 18.8M | 22.5M | |
| Enterprise Value | 16.8M | 44.4M | 2.1M | (177.2K) | 15.0M | 18.9M |
Adial Fundamentals
| Return On Equity | -1.71 | ||||
| Return On Asset | -0.88 | ||||
| Current Valuation | 2.86 M | ||||
| Shares Outstanding | 21.83 M | ||||
| Shares Owned By Insiders | 2.46 % | ||||
| Shares Owned By Institutions | 2.61 % | ||||
| Number Of Shares Shorted | 1.23 M | ||||
| Price To Earning | (1.88) X | ||||
| Price To Book | 1.57 X | ||||
| EBITDA | (13.2 M) | ||||
| Net Income | (13.2 M) | ||||
| Cash And Equivalents | 9.16 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 975.86 K | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 5.32 X | ||||
| Book Value Per Share | 0.26 X | ||||
| Cash Flow From Operations | (6.92 M) | ||||
| Short Ratio | 2.22 X | ||||
| Earnings Per Share | (0.71) X | ||||
| Target Price | 2.17 | ||||
| Beta | 1.36 | ||||
| Market Capitalization | 8.7 M | ||||
| Total Asset | 5.04 M | ||||
| Retained Earnings | (82 M) | ||||
| Working Capital | 3.08 M | ||||
| Current Asset | 1.02 M | ||||
| Current Liabilities | 452.53 K | ||||
| Net Asset | 5.04 M |
About Adial Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adial Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adial Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adial Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Adial Pharmaceuticals Piotroski F Score and Adial Pharmaceuticals Altman Z Score analysis. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.